Storia in 3 fonti

First Complement Inhibitor Wins Full Approval in IgA Nephropathy

Iptacopan significantly slowed kidney decline in a phase III trial

Raccontata da

healio.com

medpagetoday.com

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo4 g fa

First Complement Inhibitor Wins Full Approval in IgA Nephropathy

Iptacopan significantly slowed kidney decline in a phase III trial

originale

healio.com4 g fa

Fabhalta gains full FDA approval for proteinuria reduction in IgA nephropathy

The FDA granted full approval to iptacopan to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to a company press release. Iptacopan (Fabhalta,…

Leggi questa versione → originale

Timeline cronologica

venerdì 17 luglio 2026·healio.com
Fabhalta gains full FDA approval for proteinuria reduction in IgA nephropathy
The FDA granted full approval to iptacopan to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to a…
venerdì 17 luglio 2026·medpagetoday.com
First Complement Inhibitor Wins Full Approval in IgA Nephropathy
Iptacopan significantly slowed kidney decline in a phase III trial

First Complement Inhibitor Wins Full Approval in IgA Nephropathy

Confronto fonti

First Complement Inhibitor Wins Full Approval in IgA Nephropathy

Fabhalta gains full FDA approval for proteinuria reduction in IgA nephropathy

Timeline cronologica

Fabhalta gains full FDA approval for proteinuria reduction in IgA nephropathy

First Complement Inhibitor Wins Full Approval in IgA Nephropathy

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Novartis (NYSE:NVS)

This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval - Novartis (NYSE:NVS)